|1.||Clozel, Martine: 9 articles (11/2015 - 03/2002)|
|2.||Dingemanse, Jasper: 8 articles (03/2015 - 04/2002)|
|3.||Simonneau, Gérald: 8 articles (01/2013 - 12/2004)|
|4.||Humbert, Marc: 8 articles (01/2013 - 12/2004)|
|5.||Naeije, Robert: 8 articles (09/2010 - 03/2003)|
|6.||Prous, J R: 8 articles (09/2006 - 06/2004)|
|7.||Berger, Rolf M F: 7 articles (02/2014 - 07/2006)|
|8.||Sitbon, Olivier: 7 articles (01/2013 - 12/2004)|
|9.||Humbert, M: 7 articles (07/2010 - 01/2003)|
|10.||Rabasseda, X: 7 articles (09/2006 - 06/2004)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
08/01/2011 - "Bosentan has proven efficacy in pulmonary hypertension in the short term. "
12/01/2006 - "The results of this study suggest that treatment with bosentan is associated with long-term improvement in clinical variables and exercise capacity in approximately two thirds of the patients with pulmonary hypertension."
03/01/2013 - "Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device."
09/01/2009 - "Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension."
05/01/2009 - "Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension."
01/01/2012 - "These results suggest that bosentan is an effective treatment for refractory digital ulcers associated with SSc; however, liver function should be carefully monitored. "
01/01/2013 - "The reduction of ET-1 levels in DUs patients in therapy with bosentan confirms the efficacy of this molecule both for treatment and prevention of digital ulcers. "
01/01/2013 - "A few recent observations showed the efficacy of bosentan for accelerating the healing of nondigital ulcers in scleroderma patients. "
02/01/2012 - "The efficacy of bosentan on nondigital ulcers and its association with clinical features of ulcers were analysed. "
02/01/2012 - "To evaluate the efficacy of bosentan on nondigital ulcers in patients with SSc. "
|3.||Systemic Scleroderma (Systemic Sclerosis)
04/01/2015 - "We present a challenging case of PAH in a patient with systemic sclerosis in whom a marked decrease in functional capacity after the initiation of bosentan therapy led to the diagnosis of PVOD. "
10/01/2011 - "Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis."
07/01/2015 - "Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study."
12/01/2006 - "Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study."
07/01/2015 - "In systemic sclerosis (SSc), clinical evidence has shown that Bosentan may foster the regeneration of the peripheral microcirculatory network. "
|4.||Eisenmenger Complex (Eisenmenger's Syndrome)
05/01/2010 - "In Eisenmenger syndrome, treatment with bosentan significantly improved walking distance, pulmonary blood flow, and PVR. "
05/01/2006 - "This study showed a clear functional improvement in patients with Eisenmenger's syndrome treated with bosentan. "
05/29/2009 - "In this open-label study, 24 Down patients (>18 years) with Eisenmenger syndrome (17 males) were treated with bosentan. "
05/29/2009 - "In this study, we evaluate the therapeutic role of bosentan treatment in Down patients with Eisenmenger syndrome. "
06/23/2008 - "Following the 16-week, double blind, placebo-controlled BREATHE-5 study of bosentan in patients with Eisenmenger syndrome, an open-label extension (OLE) was performed. "
|5.||Heart Diseases (Heart Disease)
11/15/2011 - "The aim of this study was to retrospectively analyze the long-term efficacy and safety of bosentan in adults with PAH secondary to congenital heart disease (PAH-CHD). "
11/01/2006 - "However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD). "
07/01/2012 - "Bosentan is the only medication to date to be compared with placebo in a randomized controlled trial specifically targeting congenital heart disease-associated PAH. "
05/01/2007 - "To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). "
09/01/2006 - "Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD). "
|1.||Endothelin Receptors (Endothelin Receptor)
|2.||Idiopathic pulmonary hypertension
|5.||Endothelin-1 (Endothelin 1)
|7.||Endothelin A Receptor
|2.||Renal Dialysis (Hemodialysis)
|4.||Heart Transplantation (Grafting, Heart)